| Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice HP Montoyo, C Vaccaro, M Hafner, RJ Ober, W Mueller, ES Ward Proceedings of the National Academy of Sciences 106 (8), 2788-2793, 2009 | 216 | 2009 |
| Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model DA Patel, A Puig-Canto, DK Challa, HP Montoyo, RJ Ober, ES Ward The Journal of Immunology 187 (2), 1015-1022, 2011 | 100 | 2011 |
| Targeting p38α increases DNA damage, chromosome instability, and the anti-tumoral response to taxanes in breast cancer cells B Cánovas, A Igea, AA Sartori, RR Gomis, TT Paull, M Isoda, ... Cancer cell 33 (6), 1094-1110. e8, 2018 | 90 | 2018 |
| The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells P Muñoz-Guardiola, J Casas, E Megías-Roda, S Solé, H Perez-Montoyo, ... Autophagy 17 (6), 1349-1366, 2021 | 80 | 2021 |
| Resistance to taxanes in triple-negative breast cancer associates with the dynamics of a CD49f+ tumor-initiating population J Gómez-Miragaya, M Palafox, L Paré, G Yoldi, I Ferrer, S Vila, P Galván, ... Stem cell reports 8 (5), 1392-1407, 2017 | 78 | 2017 |
| Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis DK Challa, U Bussmeyer, T Khan, HP Montoyo, P Bansal, RJ Ober, ... MAbs 5 (5), 655-659, 2013 | 61 | 2013 |
| Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis DK Challa, X Wang, HP Montoyo, R Velmurugan, RJ Ober, ES Ward MAbs 11 (5), 848-860, 2019 | 46 | 2019 |
| Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer I Felip, CP Moiola, C Megino-Luque, C Lopez-Gil, S Cabrera, ... Gynecologic Oncology 153 (2), 425-435, 2019 | 37 | 2019 |
| Therapeutic potential of autophagy modulation in cholangiocarcinoma H Perez-Montoyo Cells 9 (3), 614, 2020 | 31 | 2020 |
| The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer A López‐Plana, P Fernández‐Nogueira, P Muñoz‐Guardiola, ... International Journal of Cancer 147 (4), 1163-1179, 2020 | 17 | 2020 |
| The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival N Diéguez-Martínez, S Espinosa-Gil, G Yoldi, E Megías-Roda, ... Cellular and Molecular Life Sciences 79 (10), 524, 2022 | 13 | 2022 |
| The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis L París-Coderch, A Soriano, C Jiménez, T Erazo, P Muñoz-Guardiola, ... Cell Death & Disease 11 (9), 773, 2020 | 10 | 2020 |
| GPBP-1 inhibition and its therapeutic use J Saus, F Revert-Ros, F Revert, C Aguado-Velasco, E López-Pascual, ... US Patent 9,066,938, 2015 | 7 | 2015 |
| Assessment of biological activity in RAW 264.7 cell line stimulated with lipopolysaccharide using dynamic laser speckle RJ González-Peña, H Pérez-Montoyo, RA Braga, DC Viana Applied Physics B 122, 1-8, 2016 | 5 | 2016 |
| Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models A Mancini, A Colapietro, L Cristiano, A Rossetti, V Mattei, GL Gravina, ... Frontiers in Oncology 12, 943064, 2022 | 3 | 2022 |
| The first-in-class anti-cancer agent ABTL0812 is effective in preclinical models of human endometrial cancer. EC Colàs, N Eritja, P Muñoz-Guardiola, S Sole-Sanchez, C Moiola, I Felip, ... Journal of Clinical Oncology 35 (15_suppl), e17070-e17070, 2017 | 3 | 2017 |
| Determination of recommended phase II dose of ABTL0812, a novel regulator of Akt/mTOR axis, by pharmacokinetic-pharmacodynamic modelling J Alfon, L Vidal, L Gaba, I Victoria, M Gil, B Laquente, M Brunet, H Colom, ... Annals of Oncology 27, vi120, 2016 | 3 | 2016 |
| ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple‐negative breast cancer models E Polonio‐Alcalá, S Solé‐Sánchez, P Muñoz‐Guardiola, E Megías‐Roda, ... Cancer Communications 42 (6), 567, 2022 | 2 | 2022 |
| ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug exhibits immunomodulatory effects that modify tumor microenvironment in pancreatic cancer models G Yoldi, P Munoz-Guardiola, E Megias, H Perez-Montoyo, ... Cancer Research 81 (13_Supplement), 1805-1805, 2021 | 2 | 2021 |
| Phase 2 clinical trial of the proautophagic drug ABTL0812 combined with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung carcinoma. J Bosch-Barrera, T Moran, P Estévez-García, P Martín-Martorell, ... Journal of Clinical Oncology 41 (16_suppl), 9059-9059, 2023 | 1 | 2023 |
